Patents by Inventor Alberdan Silva Santos

Alberdan Silva Santos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of 5-hydroxy-2-hydroxymethyl-?-pyrone (HMP) as a leishmanicidal agent
    Patent number: 9115106
    Abstract: The present invention refers to the use of HMP (a secondary metabolite obtained from Aspergillus fungi) as an agent that intensifies the mechanism of macrophage activation, leading to the death of L. (Leishmania) amazonensis, the etiologic agent of cutaneous leishmaniasis. The main mechanism of action of this agent is the activation of the microbicidal activity of host cells, through increased superoxide production, number of lysosomes, actin and microtubule filament polymerization and increased spreading, typical of activated cells. Additionally, HMP represents a molecule of easy acquisition, presents an efficient combat mechanism with no adverse reactions and capacity to inhibit the development of promastigotes and amastigotes forms. Finally, results suggest HMP to be a potential candidate for use against cutaneous leishmaniasis at a minimal concentration of 50 ?g/mL.
    Type: Grant
    Filed: August 14, 2009
    Date of Patent: August 25, 2015
    Assignee: UNIVERSIDADE FEDERAL DO PARA
    Inventors: Alberdan Silva Santos, Edilene Oliveira da Silva, Jose Luiz Martins do Nascimento, Claudio Naum Alves, Ana Paula Drumond Rodrigues, Antonio Sergio da Costa Carvalho
  • USE OF 5-HYDROXY-2-HYDROXYMETHYL-Y-PYRONE (HMP) AS A LEISHMANICIDAL AGENT
    Publication number: 20110178169
    Abstract: The present invention refers to the use of HMP (a secondary metabolite obtained from Aspergillus fungi) as an agent that intensifies the mechanism of macrophage activation, leading to the death of L. (Leishmania) amazonensis, the etiologic agent of cutaneous leishmaniasis. The main mechanism of action of this agent is the activation of the microbicidal activity of host cells, through increased superoxide production, number of lysosomes, actin and microtubule filament polymerization and increased spreading, typical of activated cells. Additionally, HMP represents a molecule of easy acquisition, presents an efficient combat mechanism with no adverse reactions and capacity to inhibit the development of promastigotes and amastigotes forms. Finally, results suggest HMP to be a potential candidate for use against cutaneous leishmaniasis at a minimal concentration of 50 ?g/mL.
    Type: Application
    Filed: August 14, 2009
    Publication date: July 21, 2011
    Inventors: Alberdan Silva Santos, Edilene Oliveira Da Silva, Jose Luiz Martins do Nascimento, Claudio Naum Alves, Ana Paul Drumond Rodrigues, Antonio Sergio da Costa Carvalho